** U.S.-listed shares of Oncolytics Biotech ONC.TO, ONCY.O rise 35.8% to $1.10 premarket
** ONCY says its pancreatic cancer therapy, pelareorep, has received regulatory approval to continue patient enrollment
** ONCY is evaluating pelareorep in combination with chemotherapy regimen Folfirinox and immunotherapy atezolizumab
** ONCY says it will move forward with full enrollment of 30 newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients in the first stage
** All 5 brokerages covering the stock rate it "buy"
** ONCY fell ~31% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.